Reinforcing the Government of India’s mission to deliver equitable healthcare, Hetero Healthcare Limited, in collaboration with Enzene Biosciences, has introduced Perzea, its most affordable biosimilar of Pertuzumab for the treatment of HER2-positive breast cancer. The launch marks a significant step toward improving access to advanced cancer therapies in India, where affordability has long been a challenge.
Pertuzumab, a globally recognized monoclonal antibody therapy, has been proven to improve clinical outcomes when administered alongside trastuzumab and chemotherapy. However, the high cost of the treatment has often placed it out of reach for many Indian patients. By launching Perzea, Hetero aims to close this treatment gap by offering an effective, world-class therapy at a fraction of the global price.
“Hetero Healthcare is proud to support the nation’s healthcare goals,” said Mr. M. Srinivas Reddy, Managing Director. “Perzea represents our responsibility to provide Indian patients with world-class therapies at a fraction of global costs.”
The initiative not only strengthens oncology access in India but also highlights the country’s emergence as a hub for biosimilar innovation and development. The partnership with Enzene Biosciences showcases how scientific collaboration, combined with scale and affordability, can transform patient outcomes in critical therapeutic areas like oncology.
Hetero Healthcare Limited has established itself as a leader in oncology, antiretrovirals, and critical care therapies. Guided by its mission to make healthcare solutions accessible and affordable, the company continues to touch millions of lives across India, expanding access to advanced treatments where they are needed the most.